Somatropin (HGH) vs Adamax
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)Cognitive Enhancement
Adamax- Summary
- Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- Half-Life
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Estimated 1-3 hours (short; peptide degradation)
- Admin Route
- Subcutaneous, Intramuscular (less common)
- Subcutaneous, Intranasal (research)
- Research
- —
- —
- Typical Dose
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- 200-400 mcg per dose
- Frequency
- Once daily
- Once daily or every other day
- Key Benefits
- Increases lean muscle mass and reduces body fat (particularly visceral)
- Restores growth hormone deficiency (FDA-approved)
- Improves bone mineral density
- Enhances exercise capacity and recovery
- Supports skin thickness and collagen synthesis
- Improves lipid profile in GHD patients
- Explored for anti-aging and cellular regeneration
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Side Effects
- Fluid retention and edema (common, dose-dependent)
- Carpal tunnel syndrome
- Joint and muscle pain
- Insulin resistance and elevated blood glucose
- +3 more
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Stacks With
- —
- —